Ninth Version AJCC/UICC TNM Staging of Nasopharyngeal Cancer
Author Information
Author(s): Pan Jian-Ji MD, Mai Hai-Qiang PhD, Ng Wai Tong MD, Hu Chao-Su MD, Li Jin-Gao MD, Chen Xiao-Zhong MD, Chow James C. H. MBChB, Wong Edwin MBBS, Lee Victor MD, Ma Ling-Yu MSc, Guo Qiao-Juan PhD, Liu Qin MBChB, Liu Li-Zhi PhD, Xu Ting-Ting MD, Gong Xiao-Chang MD, Qiang Meng-Yun MD, Au Kwok-Hung MBBS, Liu Tsz-Chim MBChB, Chiang Chi Leung MD, Xiao You-Ping PhD, Lin Shao-Jun MD, Chen Yun-Bin MD, Guo Shan-Shan PhD, Wong Charlene H. L. PhD, Tang Lin-Quan MD, Xu Zhi-Yuan MD, Jia Yi-Zhen PhD, Peng Wen-Sa MD, Hu Li-Ping MD, Lu Tian-Zhu MD, Jiang Feng MD, Cao Cai-Neng MD, Xu Wei PhD, Ma Jun MD, Blanchard Pierre MD, Williams Michelle MD, Glastonbury Christine M. MD, King Ann D. MD, Patel Snehal G. MD, Seethala Raja R. MD, Colevas A. Dimitrios MD, Fan Dai-Ming MD, Chua Melvin L. K. PhD, Huang Shao Hui MD, O’Sullivan Brian MD, Lydiatt William MD, Lee Anne W. M. DSc
Primary Institution: American Joint Committee on Cancer Expert Panel
Hypothesis
How was the ninth version of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) staging system for improving prognostication of nasopharyngeal carcinoma formulated?
Conclusion
The ninth version of TNM staging for nasopharyngeal carcinoma provides an improved staging system for global application and a framework for future incorporation of nonanatomical factors.
Supporting Evidence
- Advanced extranodal extension was identified as an independent adverse factor for all endpoints.
- Significant hazard discrimination was achieved by grouping T1-2N0-1 as stage I, T3/N2 as stage II, and T4/N3 as stage III.
- Metastatic disease was exclusively classified as stage IV, with further subdivision into IVA and IVB.
Takeaway
This study created a new way to stage nasopharyngeal cancer to help doctors better understand how to treat patients and predict their outcomes.
Methodology
This multicenter study analyzed patients with nasopharyngeal carcinoma and reviewed detailed tumor features, with data analysis completed in December 2023.
Potential Biases
Treatment heterogeneity among participating institutions may affect results.
Limitations
The study's applicability to EBV-negative keratinizing tumors requires validation, and interrater concordance was not formally assessed.
Participant Demographics
Of the 4914 patients analyzed, 1264 (25.7%) were female and 3650 (74.3%) were male; the median age was 48.1 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 1.26-2.19
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website